Trial Profile
12-week, Multicenter, Open-label, Non-comparative Study to Investigate Pharmacodynamic and Safety of Alfuzosin 0.2 mg/kg/Day in the Treatment of Children and Adolescents 2 - 16 Years of Age With Hydronephrosis Associated With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology Followed by a 40-week Open-label Extension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Nov 2014
Price :
$35
*
At a glance
- Drugs Alfuzosin (Primary)
- Indications Hydronephrosis
- Focus Registrational; Therapeutic Use
- Sponsors Sanofi
- 26 Apr 2014 New trial record